Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis

Vaccine

Volumn 26, Issue 45, 2008, Pages 5700-5711

  Kumari, Shraddha ^a   Samant, Mukesh ^a   Misra, Pragya ^a   Khare, Prashant ^a   Sisodia, Brijesh ^b   Shasany, Ajit K ^b   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

Author keywords

Hamsters; Immunoprophylaxis; MALDI TOF MS; Soluble Leishmania donovani promastigotes (SLD); Th1 stimulatory proteins

Indexed keywords

BCG VACCINE; CALRETICULIN; DISULFIDE ISOMERASE; ELONGATION FACTOR 2; ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 83; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; INTERLEUKIN 12; POLYPROTEIN; TH1 STIMULATORY POLYPROTEIN F2.4; TH1 STIMULATORY POLYPROTEIN F2.5; TH1 STIMULATORY POLYPROTEIN F2.6; TH1 STIMULATORY POLYPROTEIN F2.7; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DELAYED HYPERSENSITIVITY; FRACTIONATION; HUMAN; HUMAN CELL; IMMUNOPROPHYLAXIS; IMMUNOSTIMULATION; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN ANALYSIS; SYRIAN HAMSTER; TANDEM MASS SPECTROMETRY; TH1 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; CRICETINAE; CYTOKINES; HYPERSENSITIVITY, DELAYED; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; MALE; MESOCRICETUS; POLYPROTEINS; PROTOZOAN PROTEINS; SOLUBILITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TH1 CELLS; VACCINATION;

EID: 52949083179     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.021     Document Type: Article

References (86)

1. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14 2 (2001) 229-243
2. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27 5 (2004) 305-318
3. Murray H.W., Hariprashad J., and Coffman R.L. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J Exp Med 185 5 (1997) 867-874
4. Bhowmick S., Ravindran R., and Ali N. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 25 (2007) 6544-6556
5. Reed S.G., and Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 5 4 (1993) 524-531
6. Skeiky Y.A., Kennedy M., Kaufman D., Borges M.M., Guderian J.A., Scholler J.K., et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 161 11 (1998) 6171-6179
7. Coler R.N., Skeiky Y.A., Bernards K., Greeson K., Carter D., Cornellison C.D., et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 70 8 (2002) 4215-4225
8. Muller I., Fruth U., and Louis J.A. Immunobiology of experimental leishmaniasis. Med Microbiol Immunol 181 1 (1992) 1-12
9. Modabber F. Development of vaccines against leishmaniasis. Scand J Infect Dis Suppl 76 (1990) 72-78
10. Coler R.N., Goto Y., Bogatzki L., Raman V., and Reed S.G. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by the elicitation of CD4 + T cells. Infect Immun (2007)
11. Kamil A.A., Khalil E.A., Musa A.M., Modabber F., Mukhtar M.M., Ibrahim M.E., et al. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 97 3 (2003) 365-368
12. Khalil E.A., Ayed N.B., Musa A.M., Ibrahim M.E., Mukhtar M.M., Zijlstra E.E., et al. Dichotomy of protective cellular immune responses to human visceral leishmaniasis. Clin Exp Immunol 140 2 (2005) 349-353
13. Lemesre J.L., Holzmuller P., Goncalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25 21 (2007) 4223-4234
14. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 20 27-28 (2002) 3277-3284
15. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26 14 (2008) 1709-1724
16. Santos W.R., de Lima V.M., de Souza E.P., Bernardo R.R., Palatnik M., and Palatnik de Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21 1-2 (2002) 30-43
17. Borja-Cabrera G.P., Cruz Mendes A., Paraguai de Souza E., Hashimoto Okada L.Y., de A.T.F.A., Kawasaki J.K., et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22 17-18 (2004) 2234-2243
18. Santos W.R., Paraguai de Souza E., Palatnik M., and Palatnik de Sousa C.B. Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani. Vaccine 17 20-21 (1999) 2554-2561
19. Palatnik de Sousa C.B., Gomes E.M., de Souza E.P., dos Santos W.R., de Macedo S.R., de Medeiros L.V., et al. The FML (Fucose Mannose Ligand) of Leishmania donovani. A new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar. Rev Soc Bras Med Trop 29 2 (1996) 153-163
20. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., Palatnik M., et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 19 9-10 (2000) 1082-1092
21. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186 7 (1997) 1137-1147
22. Jardim A., Tolson D.L., Turco S.J., Pearson T.W., and Olafson R.W. The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex. J Immunol 147 10 (1991) 3538-3544
23. Jaffe C.L., Rachamim N., and Sarfstein R. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J Immunol 144 2 (1990) 699-706
24. Convit J., Castellanos P.L., Rondon A., Pinardi M.E., Ulrich M., Castes M., et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1 8530 (1987) 401-405
25. Russo D.M., Jardim A., Carvalho E.M., Sleath P.R., Armitage R.J., Olafson R.W., et al. Mapping human T cell epitopes in Leishmania gp63: identification of cross-reactive and species-specific epitopes. J Immunol 150 10 (1993) 4713
26. Garg R., and Dube A. Animal models for vaccine studies for visceral leishmaniasis. Indian J Med Res 123 3 (2006) 439-454
27. Khamesipour A., Rafati S., Davoudi N., Maboudi F., and Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 123 3 (2006) 423-438
28. Garg R., Gupta S.K., Tripathi P., Hajela K., Sundar S., Naik S., et al. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine 24 15 (2006) 2900-2909
29. Garg R., Srivastava J.K., Pal A., Naik S., and Dube A. Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis. Vaccine 23 9 (2005) 1189-1196
30. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174 11 (2005) 7160-7171
31. Melby P.C., Yang J., Zhao W., Perez L.E., and Cheng J. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69 8 (2001) 4719-4725
32. Kumari S., Kumar A., Samant M., Sundar S., Singh N., and Dube A. Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis. Proteomics-Clinical Application 3 2 (2008) 372-386
33. Gupta S.K., Sisodia B.S., Sinha S., Hajela K., Naik S., Shasany A.K., et al. Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 7 5 (2007) 816-823
34. Dube A., Singh N., and Sundar S. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 96 4 (2005) 216-223
35. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 1 (1951) 265-275
36. Mehrotra J., Mittal A., Dhindsa M.S., and Sinha S. Fractionation of mycobacterial integral membrane proteins by continuous elution SDS-PAGE reveals the immunodominance of low molecular weight subunits for human T cells. Clin Exp Immunol 109 3 (1997) 446-450
37. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 5259 (1970) 680-685
38. Wray W., Boulikas T., Wray V.P., and Hancock R. Silver staining of proteins in polyacrylamide gels. Anal Biochem 118 1 (1981) 197-203
39. Wessel D., and Flügge U.I. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138 (1984) 141-143
40. Arand M., Friedberg T., and Oesch F. Colorimetric quantitation of trace amounts of sodium lauryl sulfate in the presence of nucleic acids and proteins. Anal Biochem 207 (1992) 73-75
41. Voller A., Bidwell D.E., and Bartlett A. The enzyme linked immunosorbent assay (ELISA): a guide with abstracts of microplate application (1979), Fileroline Press, Guernsey, CI
42. Garg R., Gupta S.K., Tripathi P., Naik S., Sundar S., and Dube A. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin Exp Immunol 140 1 (2005) 149-156
43. Ding A.H., Nathan C.F., and Stuehr D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141 7 (1988) 2407-2412
44. Melby P.C., Chandrasekar B., Zhao W., and Coe J.E. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 166 3 (2001) 1912-1920
45. Shevchenko A., Wilm M., Vorm O., and Mann M. Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal Chem 68 (1996) 850-858
46. MacMicking J., Xie Q.W., and Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 15 (1997) 323-350
47. Nozaki Y., Hasegawa Y., Ichiyama S., Nakashima I., and Shimokata K. Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages. Infect Immun 65 (1997) 3644-3647
48. Khalil E.A., Elhassan A.M., Zijlstra E.E., Osman O.F., Eljack I.A., Ibrahim M.E., et al. Safety and immunogenicity of an autoclaved Leishmania major vaccine. East Afr Med J 77 9 (2000) 468-470
49. Misra A., Dube A., Srivastava B., Sharma P., Srivastava J.K., Katiyar J.C., et al. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 19 25-26 (2001) 3485-3492
50. Howard J.G., and Liew F.Y. Mechanisms of acquired immunity in leishmaniasis. Philos Trans R Soc Lond B Biol Sci 307 1131 (1984) 87-98
51. Haldar J.P., Ghose S., Saha K.C., and Ghose A.C. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 42 2 (1983) 702-707
52. Ali N., and Afrin F. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. J Parasitol 83 1 (1997) 70-75
53. Afrin F., Rajesh R., Anam K., Gopinath M., Pal S., and Ali N. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect Immun 70 12 (2002) 6697-6706
54. Kemp K., Kemp M., Kharazmi A., Ismail A., Kurtzhals J.A., Hviid L., et al. Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol 116 3 (1999) 500-504
55. Kemp K. Cytokine-producing T cell subsets in human leishmaniasis. Arch Immunol Ther Exp (Warsz) 48 3 (2000) 173-176
56. Kemp M., Kurtzhals J.A., Bendtzen K., Poulsen L.K., Hansen M.B., Koech D.K., et al. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 61 3 (1993) 1069-1073
57. Carvalho E.M., Bacellar O., Brownell C., Regis T., Coffman R.L., and Reed S.G. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152 12 (1994) 5949-5956
58. Gifawesen C., and Farrell J.P. Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect Immun 57 10 (1989) 3091-3096
59. Kenney R.T., Sacks D.L., Gam A.A., Murray H.W., and Sundar S. Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis 177 3 (1998) 815-818
60. Melby P.C., Tryon V.V., Chandrasekar B., and Freeman G.L. Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect Immun 66 5 (1998) 2135-2142
61. Ghalib H.W., Piuvezam M.R., Skeiky Y.A., Siddig M., Hashim F.A., el-Hassan A.M., et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92 1 (1993) 324-329
62. Rodrigues Junior V., Da Silva J.S., and Campos-Neto A. Selective inability of spleen antigen presenting cells from Leishmania donovani infected hamsters to mediate specific T cell proliferation to parasite antigens. Parasite Immunol 14 1 (1992) 49-58
63. Bretscher P.A., Ogunremi O., and Menon J.N. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states. Behring Inst Mitt 98 (1997) 153-159
64. Dube A., Sharma P., Srivastava J.K., Misra A., Naik S., and Katiyar J.C. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 116 Pt 3 (1998) 219-221
65. Fragaki K., Suffia I., Ferrua B., Rousseau D., Le Fichoux Y., and Kubar J. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine 19 13-14 (2001) 1701-1709
66. Carrion J., Folgueira C., and Alonso C. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Vaccine 26 20 (2008) 2537-2544
67. Kedzierski L., Zhu Y., and Handman E. Leishmania vaccines: progress and problems. Parasitology 133 Suppl (2006) S87-S112
68. Skeiky Y.A., Coler R.N., Brannon M., Stromberg E., Greeson K., Crane R.T., et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20 27-28 (2002) 3292-3303
69. Reed S.G. Leishmaniasis vaccination: targeting the source of infection. J Exp Med 194 3 (2001) F7-F9
70. Coler R.N., and Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol 21 5 (2005) 244-249
71. McCarthy J.S., Wieseman M., Tropea J., Kaslow D., Abraham D., Lustigman S., et al. Onchocerca volvulus glycolytic enzyme fructose-1,6-bisphosphate aldolase as a target for a protective immune response in humans. Infect Immun 70 2 (2002) 851-858
72. Certa U., Ghersa P., Dobeli H., Matile H., Kocher H.P., Shrivastava I.K., et al. Aldolase activity of a Plasmodium falciparum protein with protective properties. Science 240 4855 (1988) 1036-1038
73. Pal-Bhowmick I., Sadagopan K., Vora H.K., Sehgal A., Sharma S., and Jarori G.K. Cloning, over-expression, purification and characterization of Plasmodium falciparum enolase. Eur J Biochem 271 23-24 (2004) 4845-4854
74. Reynolds S.R., Dahl C.E., and Harn D.A. T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase. J Immunol 152 1 (1994) 193-200
75. Hooker C.W., and Brindley P.J. Cloning and characterisation of strain-specific transcripts encoding triosephosphate isomerase, a candidate vaccine antigen from Schistosoma japonicum. Mol Biochem Parasitol 82 2 (1996) 265-269
76. Mitsutake K., Miyazaki T., Tashiro T., Yamamoto Y., Kakeya H., Otsubo T., et al. Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia. J Clin Microbiol 34 8 (1996) 1918-1921
77. Folgueira C., Carrion J., Moreno J., Saugar J.M., Canavate C., and Requena J.M. Effects of the disruption of the HSP70-II gene on the growth, morphology, and virulence of Leishmania infantum promastigotes. Int Microbiol 11 2 (2008) 81-89
78. Garrido C., Schmitt E., Cande C., Vahsen N., Parcellier A., and Kroemer G. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2 6 (2003) 579-584
79. Suto R., and Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269 5230 (1995) 1585-1588
80. de Andrade C.R., Kirchhoff L.V., Donelson J.E., and Otsu K. Recombinant Leishmania Hsp90 and Hsp70 are recognized by sera from visceral leishmaniasis patients but not Chagas' disease patients. J Clin Microbiol 30 2 (1992) 330-335
81. Rico A.I., Del Real G., Soto M., Quijada L., Martinez A.C., Alonso C., et al. Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice. Infect Immun 66 1 (1998) 347-352
82. Probst P., Stromberg E., Ghalib H.W., Mozel M., Badaro R., Reed S.G., et al. Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning. J Immunol 166 1 (2001) 498-505
83. Debrabant A., Lee N., Pogue G.P., Dwyer D.M., and Nakhasi H.L. Expression of calreticulin P-domain results in impairment of secretory pathway in Leishmania donovani and reduced parasite survival in macrophages. Int J Parasitol 32 11 (2002) 1423-1434
84. Ben Achour Y., Chenik M., Louzir H., and Dellagi K. Identification of a disulfide isomerase protein of Leishmania major as a putative virulence factor. Infect Immun 70 7 (2002) 3576-3585
85. Kebaier C., Louzir H., Chenik M., Ben Salah A., and Dellagi K. Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response. Infect Immun 69 8 (2001) 4906-4915
86. Kumari S., Samant M., Khare P., Sundar S., Sinha S., and Dube A. Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa. Vaccine 26 (2008) 4813-4818